The primary objective of this study was to evaluate whether OROS-MPH (Concerta), relative to placebo, increases the effectiveness of standard smoking treatment (i.e., nicotine patch and individual smoking cessation counseling) in obtaining prolonged abstinence for smokers with ADHD. The study involved 255 participants, recruited from six sites.
Prolonged abstinence rates for the OROS-MPH and placebo groups did not differ significantly. OROS-MPH, relative to placebo, effectively treated ADHD and was safe and generally well tolerated.
Primary Outcomes Article: Winhusen TM, et al. Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment on Smoking Cessation Intervention in ADHD Smokers: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Clinical Psychiatry 2010;71(12):1680-1688. [get article]
- CTN-0029 Study Protocol
- Publications in the Library about CTN-0029
- Study data from NIDA Data Share
- ClinicalTrials.gov (NCT00253747)
- NIDA protocol page
All Participating Nodes: